Agilent Technologies, Inc. (NYSE:A) Forecasted to Earn FY2024 Earnings of $5.24 Per Share

Agilent Technologies, Inc. (NYSE:A) – Analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for shares of Agilent Technologies in a research report issued to clients and investors on Wednesday, September 11th. Zacks Research analyst S. Mete now expects that the medical research company will post earnings per share of $5.24 for the year, up from their previous forecast of $5.23. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.24 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2024 earnings at $1.41 EPS, Q1 2025 earnings at $1.38 EPS, Q3 2025 earnings at $1.40 EPS, Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.46 EPS, Q3 2026 earnings at $1.62 EPS and FY2026 earnings at $6.24 EPS.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business’s revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.43 EPS.

Several other analysts have also weighed in on A. Stifel Nicolaus reiterated a “buy” rating and issued a $151.00 price objective on shares of Agilent Technologies in a research note on Monday, August 26th. Robert W. Baird dropped their price objective on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a report on Thursday, May 30th. Citigroup raised their target price on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. TD Cowen upped their price target on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, JPMorgan Chase & Co. cut their price target on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $141.60.

Agilent Technologies Price Performance

Shares of NYSE A opened at $138.65 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $40.45 billion, a PE ratio of 32.78, a P/E/G ratio of 6.36 and a beta of 1.05. The firm has a fifty day simple moving average of $136.33 and a 200 day simple moving average of $139.16. Agilent Technologies has a twelve month low of $96.80 and a twelve month high of $155.35.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agilent Technologies

Large investors have recently modified their holdings of the company. Gilbert & Cook Inc. lifted its position in Agilent Technologies by 12.5% in the fourth quarter. Gilbert & Cook Inc. now owns 2,872 shares of the medical research company’s stock valued at $399,000 after purchasing an additional 320 shares during the last quarter. Principal Securities Inc. purchased a new position in shares of Agilent Technologies in the fourth quarter worth $388,000. Johnson Investment Counsel Inc. bought a new stake in Agilent Technologies during the 4th quarter valued at $231,000. Dimensional Fund Advisors LP grew its holdings in Agilent Technologies by 5.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,032,471 shares of the medical research company’s stock worth $143,550,000 after acquiring an additional 50,162 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its position in shares of Agilent Technologies by 4.8% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 22,961 shares of the medical research company’s stock valued at $3,192,000 after acquiring an additional 1,042 shares during the period. 87.42% of the stock is owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.